Berenberg Bank cuts Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) price target to €51.80

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) had its price target lowered by analysts at Berenberg Bank from €57.95 ($59.13) to €51.80 ($52.86) in a research note released Wednesday, Fly reports.

Several other research companies have also recently published reports on the FMS. Morgan Stanley began covering shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, October 18. They set an “equal weight” rating on the stock. StockNews.com began covering shares of Fresenius Medical Care AG & Co. KGaA in a Wednesday, October 12 research note. They set a “buy” rating for the company. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Monday, October 10 report. JPMorgan Chase & Co. cut its price target on Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a Monday, August 1 report. Finally, DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 report. Two research analysts gave the stock a sell rating, seven gave the stock a hold rating and three gave the stock a buy rating. According to MarketBeat data, Fresenius Medical Care AG & Co. KGaA has an average rating of “Hold” and an average target price of $42.72.

Fresenius Medical Care AG & Co. KGaA share performance

Shares of NYSE FMS traded down $0.13 during Wednesday’s trading, hitting $14.31. 113,419 shares of the company were traded, against an average volume of 1,294,651. The company has a 50-day simple moving average of $15.52 and a 200-day simple moving average of $22.71. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47. The stock has a market capitalization of $8.39 billion, a PE ratio of 9.11, a P/E/G ratio of 0.75 and a beta of 1.06. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $12.78 and a 52-week high of $35.71.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last released its quarterly earnings data on Thursday, July 28. The company reported earnings per share of $0.41 for the quarter, missing the consensus estimate of $0.45 per ($0.04). Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.70% and a net margin of 4.42%. The company posted revenue of $5.07 billion in the quarter, versus a consensus estimate of $4.80 billion. Equity research analysts expect Fresenius Medical Care AG & Co. KGaA to post 1.5 earnings per share for the current year.

Institutional entries and exits

Several institutional investors have recently increased or reduced their stake in the company. Pzena Investment Management LLC increased its stake in the shares of Fresenius Medical Care AG & Co. KGaA by 22.4% in the 1st quarter. Pzena Investment Management LLC now owns 11,577,632 shares of the company valued at $389,935,000 after purchasing an additional 2,118,186 shares in the last quarter. Millennium Management LLC purchased a new equity position in Fresenius Medical Care AG & Co. KGaA in Q2, valued at approximately $16,738,000. Bank of America Corp DE increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% in Q1. Bank of America Corp DE now owns 1,083,689 shares of the company valued at $36,499,000 after purchasing an additional 236,459 shares in the last quarter. Cambiar Investors LLC increased its stake in the shares of Fresenius Medical Care AG & Co. KGaA by 18.3% in the 1st quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company valued at $45,935,000 after purchasing an additional 210,819 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new equity position in Fresenius Medical Care AG & Co. KGaA in Q2, valued at approximately $3,666,000. Institutional investors and hedge funds own 5.59% of the company’s shares.

About Fresenius Medical Care AG & Co. KGaA

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Read more

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five actions that top analysts are quietly whispering to their clients to buy now before the market spreads… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.